產(chǎn)品詳情
簡單介紹：
Anti-LILRA2/CD85h抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-LILRA2/CD85h抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-LILRA2/CD85h
Cat. Number:
Anti-LILRA2/CD85h抗體KL-18249R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene encodes a member of a family of immunoreceptors that are expressed predominantly on monocytes and B cells, and Anti-LILRA2/CD85h抗體at lower levels on dendritic cells and natural killer cells. The encoded protein is an activating receptor that inhibits dendritic cell differentiation and antigen presentation and suppresses innate immune response. Alternatively spliced transcript variants encoding different isoforms have been found. This gene is located in a cluster of related genes on chromosome 19 and there is a pseudogene for this gene on chromosome 3. [provided by RefSeq, Mar 2014]
Also known as:
CD85 antigen-like family memberAnti-LILRA2/CD85h抗體 H; CD85h; ILT-1; ILT1; Immunoglobulin like transcript 1; Immunoglobulin-like transcript 1; Leukocyte immunoglobulin like receptor 7; Leukocyte immunoglobulin like receptor subfamily A member 2; Leukocyte immunoglobulin-like receptor 7; Leukocyte immunoglobulin-like receptor subfamily A member 2; LILRA2; LIR-7; LIR7; LIRA2_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated Anti-LILRA2/CD85h抗體synthetic peptide derived from human LILRA2/CD85h.
●
Predicted Molecular Weight: 51kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-LILRA2/CD85h抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
